Bimekizumab for pyoderma gangrenosum ulcers
Treatments studied
Part of Injuries & trauma, Skin clinical trials.
This study tests whether the drug bimekizumab can help heal ulcers caused by a rare skin condition called pyoderma gangrenosum (PG). If you have PG and are already taking prednisone, this trial may offer a new treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- You must have at least one pyoderma gangrenosum (PG) ulcer, which is a deep skin sore with a raised, purple border
- You must be receiving wound care at least once a week
- You must be on a stable dose of 20 mg per day of the steroid prednisone for at least 2 weeks before starting
- You must be willing to undergo 4 to 6 skin biopsies during the study
- You must be able to travel to the study site for visits and have internet access for remote video visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether guselkumab (Tremfya) can help heal painful ulcers from Pyoderma Gangrenosum (PG). Participants must already be taking steroid medication and have a PG ulcer that is at least 4 cm².
This trial tests whether the drug spesolimab can help people with a skin condition called pyoderma gangrenosum, which causes painful ulcers. It's for adults who have at least one active ulcer that's at least 2 inches across and needs treatment.
This trial tests an injection called SHR-1139 for people with pyoderma gangrenosum (a rare skin condition that causes painful ulcers). If you have at least one ulcer that is 5 cm² or larger and your PARACELSUS score is at least 10, you may be able to join.
This study tests an investigational drug called SHR-1139 for adult patients with ulcerative pyoderma gangrenosum (a type of painful skin ulcer). The goal is to see if the drug is safe and helps heal the ulcers.
This study tests a cream called ruxolitinib for people with pyoderma gangrenosum, a condition that causes painful skin ulcers. The cream is applied directly to the ulcer, and the study aims to see if it helps heal the wounds.
This trial tests a new drug, bimekizumab, for people with PRP, a rare skin condition. It may help reduce skin redness, scaling, and itching.
Hear when a new Pyoderma Gangrenosum trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.